17
Disclosures
Jan 16, 2026 — Apr 17, 2026
Date Range
GROWTH
Market Segment
Pharmaceutical
Sector

Disclosures

DateTypeHeadlinePDF
Apr 17 Equity Issuance Symbio Pharmaceuticals Issues 30,827 Stock Options PDF
Apr 17 Equity Issuance Symbio Pharmaceuticals Issues 8,943 Stock Options PDF
Apr 1 Equity Issuance Symbio Pharmaceuticals Reports Monthly Exercise Status of Warrants PDF
Mar 30 Other Symbio Pharmaceuticals Extends Multiple Sclerosis Joint Research with NIH/NINDS PDF
Mar 27 Other Symbio Pharmaceuticals Exercises Early Call Option on Sixth-Eighteenth Tranche Warrant PDF
Mar 25 Other SymBio Pharmaceuticals: SymBio Pharma Shareholders Approve Key Resolutions at Annual Meeting PDF
Mar 24 Admin SymBio Pharmaceuticals: Appoints New Board Members and Executives PDF
Mar 24 Dividend SymBio Pharmaceuticals: Issues 35,000 Stock Options PDF
Mar 24 Dividend SymBio Pharmaceuticals: Issues 9,000 Stock Options PDF
Mar 23 Earnings SymBio Pharmaceuticals: Adjusts Bond Conversion and Repayment Status; Funds Reallocation Announced PDF
Mar 17 Other Completes First Patient Enrollment in Global Phase III Trial for AdV Infections Post-Hematopoietic Stem Cell Transplantation PDF
Mar 16 Other Secures Patent for IV BCV in Lymphoma Treatment PDF
Feb 19 Other SymBio Pharmaceuticals Limited Announces Amendment to Articles of Incorporation PDF
Feb 5 Earnings Symbio Pharmaceuticals Limited Reports FY25 Revenue of 1.31 billion, Down 47% PDF
Feb 2 Equity Issuance SymBio Pharma Reports January Exercise Status of Warrants PDF
Feb 2 Other SymBio Pharma Signs NIH Pact for PML Trial PDF
Jan 16 Equity Issuance SymBio Pharmaceuticals Reports Massive Exercise of Sixth-Fiveth Warrant Issue PDF

Disclosure Types

Other: 7 Equity Issuance: 5 Dividend: 2 Earnings: 2 Admin: 1